Means of evaluation and protection from doxorubicin-induced cardiotoxicity and hepatotoxicity in rats

Journal of Cancer Research and Therapeutics

Volumn 10, Issue 2, 2014, Pages 274-278

  Salouege, Issam ^a,b   Ali, Ridha ^a,b   Saïd, Dorra ^a   Elkadri, Noomen ^c   Kourda, Nadia ^d   Lakhal, Mohamed ^a   Klouz, Anis ^a,b  

^a Centre National de Pharmacovigilance   (Tunisia)

^b UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^c MILITARY HOSPITAL OF TUNIS   (Tunisia)

^d CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

Cardiac scintigraphy; cardiotoxicity; doxorubicin; hepatotoxicity; trimetazidine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; TRIMETAZIDINE;

ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; DRUG-INDUCED LIVER INJURY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; LIVER; MALE; METABOLISM; PATHOLOGY; PREVENTION AND CONTROL; TISSUE DISTRIBUTION; TOXICITY; WISTAR RAT;

ALANINE TRANSAMINASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG-INDUCED LIVER INJURY; LIVER; MALE; MYOCARDIUM; RATS, WISTAR; STROKE VOLUME; TISSUE DISTRIBUTION; TRIMETAZIDINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84905689607     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.136557     Document Type: Article

References (28)

1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Antracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
2. Danesi R, Fogli S, Gennari A, Conte P, Del Tacca M. Pharmacokineticpharmacodynamic relationship of the anthracycline anticancer drugs. Clin Pharmacokinet 2002;41:431-44.
3. Huigsloot M, Tijdens IB, Mulder GJ, van de Water B. Differential regulation of doxorubicin induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary adenocarcinoma (MTLn3) cells. J Biol Chem 2002;277:35869-79.
4. Olli JA, Antti S, Kari P Markku K, Martti P, Liisa-Maria V. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000;60:1789-92.
5. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 2001;61:771-7.
6. Ferreira AL, Matsubara LS, Matsubara BB. Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 2008;6:278-81.
7. Hideg K, Kálai T. Novel antioxidants in anthracycline cardiotoxicity. Cardiovasc Toxicol 2007;7:160-4.
8. Xiang P, Deng HY, Li K, Huang GY, Chen Y, Tu L, et al. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: Upregulation of Akt and Erk phosphorylation in a rat model. Cancer Chemother Pharmacol 2009;63:343-9.
9. Mouquet F, Rousseau D, Domergue-Dupont V, Grynberg A, Liao R. Effects of trimetazidine, a partial inhibitor of fatty acid oxidation, on ventricular function and survival after myocardial infarction and reperfusion in the rat. Fundam Clin Pharmacol 2010;24:469-76.
10. Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005;39:893-9.
11. Andersen A, Warren DJ, Slordal L. Asensitive and simple highperformance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther Drug Monit 1993;30:433-8.
12. Fogli S, Danesi R, Innocenti F, Di Paolo A, Bocci G, Barbara C. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin and their 13 dihydro metabolites in human plasma. Ther Drug Monit 1999;21:367-75.
13. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection after heart transplantation. J Heart Transplant 1990;9:588-93.
14. Huang YS, Lee SD, Deng JF, Wu JC, Lu RH, Lin YF, et al. Measuring lidocaine metabolite-monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993;19:140-7.
15. Oellerich M, Amstrong VW. The MEGX test: A tool for the real-time assessment of hepatic function. Ther Drug Monit 2001;23:81-92.
16. Alexson SE, Diczfalusy M, Halldin M, Swedmark S. Involvement of liver carboxylesterases in the in vitro metabolism of lidocaine. Drug Metab Dispos 2002;30:643-7.
17. Ikeda Y, Aih AK, Akaike M, Sato T, Ishikawa K, Ise T, et al. Androgen receptor conteracts doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol 2010;24:1338-48.
18. Ascensao A, Lumini-Oliveira J, Machado NG, Ferreira RM, Gonçalves IO, Moreira AC, et al. Acute exercise protects against calcium-induced cardiac mitochondrial permeability transition pore opning in doxorubicin-treated rats. Clin Sci (Lond) 2011;120:37-49.
19. Montaigne D, Hurt C, Neviere R. Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies. Biochem Res Int 2012;2012:1-12.
20. Montaigne D, Marechal X, Preau S, Baccouch R, Modine T, Fayad G, et al. Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. Mitochondrion 2011;11:22-6.
21. Xu M, Sheng L, Zhu X, Zeng S, Chi D, Zhang GJ. Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats. Tumori 2010;96:460-4.
22. Todorova VK, Kaufmann Y, Hennings L, Klimberg VS. Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumorbearing rats. J Nutr 2010;140:44-8.
23. Torres VM, Srdjenovic B, Jacevic V, Simic VD, Djordjevic A, Simplício AL. Fullerenol C60(OH)24 prevents doxorubicin-induced acute cardiotoxicity in rats. Pharmacol Rep 2010;62:707-18.
24. Goormaghtigh E, Ruysschaert JM. Antracycline glycoside-membrane interactions. Biochim Biophys Acta 1984;779:271-88.
25. Alvarez-Cedrón L, Sayalero ML, Lanao JM. High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. J Chromatogr B Biomed Sci Appl 1999;721:271-8.
26. Raškovi A, Stilinovi N, Kolarovi J, Vasovi V, Vukmirovi S, Mikov M. The protective effects of silymarin against doxorubicininduced cardiotoxicity and hepatotoxicity in rats. Molecules 2011;16:8601-13.
27. Hauet T, Baumert H, Amor IB, Gibelin H, Tallineau C, Eugene M, et al. Pharmacological limitation of damage to renal medulla after cold storage and transplantation by trimetazidine. J Pharmacol Exp Ther 2000;292:254-60.
28. Morin D, Sapena R, Elimadi A, Testa B, Labidalle S, Le Ridant A, et al. [(3)H]-trimetazidine mitochondrial binding sites: Regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance. Br J Pharmacol 2000;130:655-63.